Hydroxyurea‑induced superinfected ulcerations: Two case reports and review of the literature

Iancu,Gabriela Mariana; Ocneanu,Anca; Rotaru,Maria

doi:10.3892/etm.2020.9321

Hydroxyurea‑induced superinfected ulcerations: Two case reports and review of the literature

Authors:
- Gabriela Mariana Iancu
- Anca Ocneanu
- Maria Rotaru
View Affiliations

Affiliations: Dermatology Department, Faculty of Medicine, University Lucian Blaga of Sibiu, 550169 Sibiu, Romania, Dermatology Office, Grivita Medical Center, 810521 Braila, Romania
Published online on: October 14, 2020 https://doi.org/10.3892/etm.2020.9321
Article Number: 191
Copyright: © Iancu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The chronic use of hydroxyurea (HU) in some oncologic and non‑oncologic diseases (psoriasis, sickle cell anemia) can be accompanied by side effects, both systemic and mucocutaneous. The most severe adverse events known in HU therapy are leg ulcers and cutaneous carcinomas. At skin level may also appear: xerosis, persistent pruritus, skin color changes (erythema, hyperpigmentation), cutaneous atrophy. Likewise, oral ulcerations and stomatitis may occur at mucosal level. Hair damage can be expressed through alopecia and nail damage through melanonychia and oncycholysis. First case, a 63‑year‑old woman with severe psoriasis vulgaris and chronic granulocytic leukemia, with 5 years of HU therapy, was admitted to hospital for submammary and palmoplantar ulcers, superinfected with methicillin‑resistant Staphylococcus aureus and Proteus mirabilis. Clinical exam showed that the patient had also cutaneous atrophy, marked palmoplantar xerosis and melanonychia. The second case, a 72‑year‑old woman with primary thrombocytemia, treated with HU for 3 years, presented with necrotic leg ulcers that were superinfected with Pseudomonas aeruginosa, Enterobacter and E. Coli. The patient associates cellulitis, microbial eczema and xeroderma. In both cases, after HU discontinuation, systemic antibiotics, topical epithelizing agents and emollients, the ulcers had a slow favorable evolution. In our cases, the ulcers appeared after 5, respectively 3 years of HU therapy. It is stressed that in the first case, which had associated psoriasis, after 1 year of 1 g of HU/day, the psoriatic lesions completely disappeared. The severe progression of the ulcers was also favored by the superinfection of the ulcers with 2, respectively, 3 identified germs for which appropriate systemic antibiotics was required.

View Figures

View References

1	Gwilt PR and Tracewell WG: Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet. 34:347–358. 1998.PubMed/NCBI View Article : Google Scholar
2	Yarbro JW: Mechanism of action of hydroxyurea. Semin Oncol. 19 (3 Suppl 9):S1–S10. 1992.PubMed/NCBI
3	National Library of Medicine (US), National Center for Biotechnology Information: PubChem Compound Summary for CID 3657, Hydroxyurea. urihttps://pubchem.ncbi.nlm.nih.gov/compound/Hydroxyureasimplehttps://pubchem.ncbi.nlm.nih.gov/compound/Hydroxyurea. Accessed August 4, 2020.
4	Chaine B, Neonato MG, Girot R and Aractingi S: Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol. 137:467–470. 2001.PubMed/NCBI
5	Dissemond J and Körber A: Hydroxyurea-induced ulcers on the leg. CMAJ. 180(1132)2009.PubMed/NCBI View Article : Google Scholar
6	França ER, Teixeira MA, Matias Kde F, Antunes DE, Braz Rde A and Silva CE: Cutaneous effects after prolonged use of hydroxyurea in polycythemia Vera. An Bras Dermatol. 86:751–754. 2011.PubMed/NCBI View Article : Google Scholar
7	Branisteanu DE, Nichifor M, Dorobat CM, Branisteanu DC, Petrariu FD, Molodoi AD, Radu DC and Boda D: Use of textile biomaterials for the topic treatment of chronic venous disease. Rom Biotechnol Lett. 20:10618–10625. 2015.
8	Grigore O, Mihailescu AI, Solomon I, Boda D and Caruntu C: Role of stress in modulation of skin neurogenic inflammation. Exp Ther Med. 17:997–1003. 2019.PubMed/NCBI View Article : Google Scholar
9	Oakley A: Hydroxyurea. DermNet NZ, New Zealand, 2001. urihttps://www.dermnetnz.org/topics/hydroxyureasimplehttps://www.dermnetnz.org/topics/hydroxyurea. Accessed June 23, 2019.
10	Hoff NP, Akanay-Diesel S, Pippirs U, Schulte KW and Hanneken S: Cutaneous side effects of hydroxyurea treatment for polycythemia Vera. Hautarzt. 60:783–787. 2009.PubMed/NCBI View Article : Google Scholar : (In German).
11	Soutou B and Aractingi S: Myeloproliferative disorder therapy: Assessment and management of adverse events - a dermatologist's perspective. Hematol Oncol. 27 (Suppl 1):S11–S13. 2009.PubMed/NCBI View Article : Google Scholar
12	Gropper CA, Don PC and Sadjadi MM: Nail and skin hyperpigmentation associated with hydroxyurea therapy for polycythemia Vera. Int J Dermatol. 32:731–733. 1993.PubMed/NCBI View Article : Google Scholar
13	Neynaber S, Wolff H, Plewig G and Wienecke R: Longitudinal melanonychia induced by hydroxyurea therapy. J Dtsch Dermatol Ges. 2:588–5891. 2004.PubMed/NCBI View Article : Google Scholar : (In German).
14	Wiechert A, Reinhard G, Tüting T, Uerlich M, Bieber T and Wenzel J: Multiple skin cancers in a patient treated with hydroxyurea. Hautarzt. 60:651–652, 654. 2009.PubMed/NCBI View Article : Google Scholar : (In German).